AIDP Gets Magnesium Patent for Metabolic Disorders

September 20, 2012

Typical metabolic disorders include, but are not limited to, obesity and diabetes.

AIDP (City of Industry, CA) has gained a U.S. patent for its branded ingredient Magtein magnesium L-threonate in the area of metabolic health. Magtein has been initially promoted as a cognitive-health ingredient.

The patent, No. 8,163,301, is titled “Magnesium compositions and uses thereof for metabolic disorders.” It not only covers Magtein’s unique magnesium compositions but also the use of food, dietary supplements, and drugs containing magnesium L-threonate to combat the effects of metabolic disorder.

Typical metabolic disorders include, but are not limited to, obesity and diabetes. Magtein’s other patents lie in the area of neurological disorders (patent 8,142,803) and food compositions (patent 8,178,132).